已发表论文

纳布啡联合丙泊酚在无痛宫腔镜检查中的有效剂量

 

Authors Zhong W , Chen C, Tang W

Received 26 March 2022

Accepted for publication 31 May 2022

Published 11 June 2022 Volume 2022:15 Pages 5609—5614

DOI https://doi.org/10.2147/IJGM.S367449

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser

Purpose: Nalbuphine is becoming a common analgesic used in hysteroscopic operations. The aim of this study was to identify the median effective dose (ED50) and 95% effective dose (ED95) of nalbuphine combined with propofol in painless hysteroscopy.
Patients and Methods: Twenty-five patients aged 18– 60 years with an American Society of Anesthesiologists classification of I–II who were scheduled for painless hysteroscopy were recruited. The initial dose of nalbuphine was set at 0.15 mg/kg and varied by 0.01 mg/kg according to the Dixon sequential method. The ED50/ED95 of nalbuphine combined with propofol for hysteroscopy was calculated by the probit method.
Results: The ED50 of nalbuphine was 0.122 (95% confidence interval (CI) 0.092– 0.137) mg/kg, and the ED95 of nalbuphine was 0.153 (95% CI 0.138– 0.361) mg/kg.
Conclusion: The ED50/ED95 values of nalbuphine combined with propofol in painless hysteroscopy are 0.122 mg/kg and 0.153 mg/kg, respectively. Nalbuphine at 0.153 mg/kg combined with propofol is effective and safe for painless hysteroscopy.
Keywords: nalbuphine, propofol, hysteroscopy, effective dose, ED50, ED95